Last updated: 11/07/2018 02:45:12
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study. The most up to date information is available on clinicaltrials.gov.
Phase I study of Pazopanib Alone and In Combination with Lapatinib in Japanese Patients with Solid Tumors
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Trial overview
Official title: A Phase I, Open-Label, Multiple Dose of Pazopanib Alone and In Combination with Lapatinib in Japanese Patients with Solid Tumors
Trial description: This is a two part phase I study in Japanese patients that will determine the safety, tolerability and pharmacokinetics of pazopanib monotherapy and of pazopanib in combination with lapatinib.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Safety and tolerability
Timeframe: before and after taking the study medications
Secondary outcomes:
Pharmacokinetics
Timeframe: over a 24 hour period
Tumor response
Timeframe: 9 weeks
Interventions:
Enrollment:
30
Primary completion date:
2010-30-08
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Inoue M, Ando Y, Kawada K, et al.Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.Cancer Chemother Pharmacol.2014;73(4):673-83doi: 10.1007/s00280-014-2374-3
Medical condition
Carcinoma, Renal Cell
Product
lapatinib, pazopanib
Collaborators
Not applicable
Study date(s)
September 2007 to October 2015
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
20+ years
Accepts healthy volunteers
No
- Signed informed consent.
- Histologically or cytologically confirmed diagnosis of advanced solid tumor.
- Prior treatment with pazopanib, and with lapatinib for combo part.
- Clinically significant gastrointestinal abnormalities.
Inclusion and exclusion criteria
Inclusion criteria:
- Signed informed consent.
- Histologically or cytologically confirmed diagnosis of advanced solid tumor.
- Women and men with potential to have children must be willing to practice acceptable methods of birth control during the study.
- ECOG performance status of 0 or 1.
- Adequate bone marrow reserve and hepato-renal function.
- Able to swallow and retain oral medication.
- For combo part, left ventricular ejection fraction within normal range or above 50%.
Exclusion criteria:
- Prior treatment with pazopanib, and with lapatinib for combo part.
- Clinically significant gastrointestinal abnormalities.
- Sevier diseases or conditions other than cancer.
- Poorly controlled hypertension.
- Use of warfarin for therapeutic anticoagulation.
- Use of other anti-angiogenesis agents, and other ErbB inhibitors for combo part.
- Unresolved and/or unstable toxicities
- Pregnant or lactating females
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
No longer a GSK study
Actual primary completion date
2010-30-08
Actual study completion date
2015-14-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Results for study 109693 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website